Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma C Thomson

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Cell|February 23, 2021
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunityEmma C Thomson, Laura E Rosen, James G Shepherd, et al.
Plos Biology|February 25, 2021
A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 researchSuzannah J Rihn, Andres Merits, Siddharth Bakshi, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Cell|February 23, 2021
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunityEmma C Thomson, Laura E Rosen, James G Shepherd, et al.
Plos Biology|February 25, 2021
A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 researchSuzannah J Rihn, Andres Merits, Siddharth Bakshi, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 11